Anavex Life Sciences Corp. (0HFR.L)
USD 8.82
(0.8%)
USD 8.82
(0.8%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 55.75 Million USD | 9.36% |
| 2022 | 50.98 Million USD | 21.55% |
| 2021 | 41.94 Million USD | 35.58% |
| 2020 | 30.93 Million USD | 7.39% |
| 2019 | 28.8 Million USD | 50.16% |
| 2018 | 19.18 Million USD | 23.46% |
| 2017 | 15.53 Million USD | 4.45% |
| 2016 | 14.87 Million USD | 109.27% |
| 2015 | 7.1 Million USD | 139.43% |
| 2014 | 2.96 Million USD | 39.19% |
| 2013 | 2.13 Million USD | -50.57% |
| 2012 | 4.31 Million USD | -30.18% |
| 2011 | 6.18 Million USD | 9.56% |
| 2010 | 5.64 Million USD | 19.17% |
| 2009 | 4.73 Million USD | -10.17% |
| 2008 | 5.26 Million USD | 233.97% |
| 2007 | 1.57 Million USD | 6065.93% |
| 2006 | 25.59 Thousand USD | -72.04% |
| 2005 | 91.54 Thousand USD | 532.8% |
| 2004 | 14.46 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.51 Million USD | 10.86% |
| 2024 Q1 | 11.29 Million USD | -10.74% |
| 2024 Q3 | 14.72 Million USD | 17.65% |
| 2023 Q3 | 13.53 Million USD | -4.64% |
| 2023 FY | 55.75 Million USD | 9.36% |
| 2023 Q2 | 14.18 Million USD | -7.62% |
| 2023 Q1 | 15.35 Million USD | 0.49% |
| 2023 Q4 | 12.65 Million USD | -6.49% |
| 2022 Q3 | 12.45 Million USD | 8.15% |
| 2022 Q1 | 11.72 Million USD | -4.31% |
| 2022 FY | 50.98 Million USD | 21.55% |
| 2022 Q4 | 15.28 Million USD | 22.68% |
| 2022 Q2 | 11.51 Million USD | -1.74% |
| 2021 Q3 | 11.35 Million USD | 26.96% |
| 2021 Q4 | 12.25 Million USD | 7.89% |
| 2021 FY | 41.94 Million USD | 35.58% |
| 2021 Q1 | 9.39 Million USD | 25.15% |
| 2021 Q2 | 8.94 Million USD | -4.81% |
| 2020 Q2 | 7.69 Million USD | 0.95% |
| 2020 FY | 30.93 Million USD | 7.39% |
| 2020 Q3 | 8.1 Million USD | 5.3% |
| 2020 Q4 | 7.5 Million USD | -7.38% |
| 2020 Q1 | 7.62 Million USD | 21.6% |
| 2019 Q2 | 8.06 Million USD | 9.01% |
| 2019 FY | 28.8 Million USD | 50.16% |
| 2019 Q1 | 7.39 Million USD | 27.25% |
| 2019 Q3 | 7.07 Million USD | -12.32% |
| 2019 Q4 | 6.27 Million USD | -11.33% |
| 2018 Q4 | 5.81 Million USD | 27.97% |
| 2018 Q3 | 4.54 Million USD | -4.03% |
| 2018 FY | 19.18 Million USD | 23.46% |
| 2018 Q1 | 4.09 Million USD | -20.97% |
| 2018 Q2 | 4.73 Million USD | 15.7% |
| 2017 Q1 | 3.13 Million USD | -52.2% |
| 2017 FY | 15.53 Million USD | 4.45% |
| 2017 Q3 | 3.63 Million USD | 1.22% |
| 2017 Q2 | 3.59 Million USD | 14.64% |
| 2017 Q4 | 5.17 Million USD | 42.39% |
| 2016 Q4 | 6.55 Million USD | 191.88% |
| 2016 Q1 | 3.92 Million USD | -1.12% |
| 2016 FY | 14.87 Million USD | 109.27% |
| 2016 Q2 | 2.15 Million USD | -45.1% |
| 2016 Q3 | 2.24 Million USD | 4.3% |
| 2015 FY | 7.1 Million USD | 139.43% |
| 2015 Q4 | 3.96 Million USD | 162.18% |
| 2015 Q3 | 1.51 Million USD | 76.27% |
| 2015 Q2 | 858.33 Thousand USD | 11.37% |
| 2015 Q1 | 770.67 Thousand USD | 20.54% |
| 2014 Q4 | 639.36 Thousand USD | -35.99% |
| 2014 Q3 | 998.83 Thousand USD | -2.19% |
| 2014 Q2 | 1.02 Million USD | 230.58% |
| 2014 FY | 2.96 Million USD | 39.19% |
| 2014 Q1 | 308.9 Thousand USD | -78.93% |
| 2013 Q1 | 415.37 Thousand USD | -35.24% |
| 2013 FY | 2.13 Million USD | -50.57% |
| 2013 Q4 | 1.46 Million USD | 1070.18% |
| 2013 Q2 | 126.4 Thousand USD | -69.57% |
| 2013 Q3 | 125.27 Thousand USD | -0.89% |
| 2012 Q3 | 696.34 Thousand USD | -12.37% |
| 2012 Q4 | 641.38 Thousand USD | -7.89% |
| 2012 FY | 4.31 Million USD | -30.18% |
| 2012 Q2 | 794.65 Thousand USD | -63.65% |
| 2012 Q1 | 2.18 Million USD | 78.24% |
| 2011 Q3 | 1.63 Million USD | -15.87% |
| 2011 Q1 | 1.36 Million USD | -30.31% |
| 2011 FY | 6.18 Million USD | 9.56% |
| 2011 Q4 | 1.22 Million USD | -25.08% |
| 2011 Q2 | 1.94 Million USD | 42.34% |
| 2010 FY | 5.64 Million USD | 19.17% |
| 2010 Q4 | 1.96 Million USD | 50.72% |
| 2010 Q3 | 1.3 Million USD | -14.24% |
| 2010 Q2 | 1.51 Million USD | 76.28% |
| 2010 Q1 | 860.88 Thousand USD | -52.2% |
| 2009 Q1 | 905.84 Thousand USD | -66.28% |
| 2009 Q2 | 777.79 Thousand USD | -14.14% |
| 2009 Q3 | 1.25 Million USD | 61.6% |
| 2009 Q4 | 1.8 Million USD | 43.3% |
| 2009 FY | 4.73 Million USD | -10.17% |
| 2008 Q3 | 994.96 Thousand USD | 48.12% |
| 2008 Q2 | 671.73 Thousand USD | -26.75% |
| 2008 FY | 5.26 Million USD | 233.97% |
| 2008 Q1 | 917.02 Thousand USD | -19.61% |
| 2008 Q4 | 2.68 Million USD | 169.96% |
| 2007 Q3 | 255.56 Thousand USD | 51.42% |
| 2007 FY | 1.57 Million USD | 6065.93% |
| 2007 Q2 | 168.78 Thousand USD | 1267.88% |
| 2007 Q4 | 1.14 Million USD | 346.37% |
| 2007 Q1 | 12.33 Thousand USD | 111.1% |
| 2006 Q3 | 5680.00 USD | 21.89% |
| 2006 Q4 | 5845.00 USD | 2.9% |
| 2006 FY | 25.59 Thousand USD | -72.04% |
| 2006 Q1 | 9407.00 USD | -77.47% |
| 2006 Q2 | 4660.00 USD | -50.46% |
| 2005 FY | 91.54 Thousand USD | 532.8% |
| 2005 Q3 | 45.69 Thousand USD | 0.0% |
| 2005 Q2 | 45.69 Thousand USD | 1015.13% |
| 2005 Q4 | 41.74 Thousand USD | -8.65% |
| 2005 Q1 | 4098.00 USD | 0.0% |
| 2004 FY | 14.46 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 80.442% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -14.956% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -359.237% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 97.364% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 86.361% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 96.903% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 86.962% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 79.776% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 88.295% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 96.807% |
| bluebird bio, Inc. | 240.23 Million USD | 76.791% |
| Blueprint Medicines Corporation | 722.86 Million USD | 92.287% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 60.863% |
| Imunon, Inc. | 21.03 Million USD | -165.121% |
| Adicet Bio, Inc. | 152.03 Million USD | 63.328% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 84.874% |
| Dynavax Technologies Corporation | 219.14 Million USD | 74.557% |
| Editas Medicine, Inc. | 247.3 Million USD | 77.454% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 94.659% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 79.494% |
| Exelixis, Inc. | 1.58 Billion USD | 96.486% |
| FibroGen, Inc. | 398.11 Million USD | 85.995% |
| Geron Corporation | 70.44 Million USD | 20.847% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 81.372% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 53.79% |
| Illumina, Inc. | 3.81 Billion USD | 98.538% |
| Incyte Corporation | 1.19 Billion USD | 95.317% |
| Insmed Incorporated | 949.26 Million USD | 94.126% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 89.891% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 92.848% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 87.637% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 97.284% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -42.405% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 94.882% |
| Evolus, Inc. | 189.75 Million USD | 70.617% |
| Myriad Genetics, Inc. | 600.1 Million USD | 90.709% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.508% |
| OPKO Health, Inc. | 574.68 Million USD | 90.298% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 95.903% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 89.46% |
| Verastem, Inc. | 92.08 Million USD | 39.451% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.863% |
| Waters Corporation | 943.51 Million USD | 94.091% |
| Zoetis Inc. | 2.76 Billion USD | 97.984% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.832% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.456% |
| Biogen Inc. | 5.2 Billion USD | 98.929% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 75.618% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.02% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -300.844% |
| Homology Medicines, Inc. | 9.87 Million USD | -464.618% |
| Nektar Therapeutics | 190.9 Million USD | 70.794% |
| TG Therapeutics, Inc. | 198.47 Million USD | 71.908% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 44.701% |
| Perrigo Company plc | 1.52 Billion USD | 96.352% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -24.826% |